Dieckmann, Klaus-Peter
Dumlupinar, Cansu
Radtke, Arlo
Matthies, Cord
Pichler, Renate
Paffenholz, Pia
Sommer, Jörg
Winter, Alexander
Zengerling, Friedemann
Hennig, Finja
Wülfing, Christian
Belge, Gazanfer http://orcid.org/0000-0001-8613-3450
Funding for this research was provided by:
Deutsche Krebshilfe (70 11 31 86)
Universität Bremen
Article History
Received: 30 April 2021
Accepted: 30 October 2021
First Online: 14 November 2021
Declarations
:
: KPD and GB each possess 9.7% ownership shares of mirdetect GmbH, Bremerhaven, a start-up company aiming to develop a commercially available test for measuring miRs in serum. mirdetect holds a patent for the measurement of miR in body fluids at the limit of detection. AR is an employee of mirdetect GmbH, Bremerhaven, since the beginning of 2019. All other authors declare no competing interests towards this report.